![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SEMA3F |
Gene summary for SEMA3F |
![]() |
Gene information | Species | Human | Gene symbol | SEMA3F | Gene ID | 6405 |
Gene name | semaphorin 3F | |
Gene Alias | SEMA-IV | |
Cytomap | 3p21.31 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | C9JPG5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6405 | SEMA3F | C30 | Human | Oral cavity | OSCC | 7.67e-17 | 7.28e-01 | 0.3055 |
6405 | SEMA3F | C43 | Human | Oral cavity | OSCC | 7.33e-09 | 1.14e-01 | 0.1704 |
6405 | SEMA3F | C46 | Human | Oral cavity | OSCC | 1.17e-08 | 1.55e-01 | 0.1673 |
6405 | SEMA3F | C51 | Human | Oral cavity | OSCC | 7.80e-17 | 7.39e-01 | 0.2674 |
6405 | SEMA3F | C57 | Human | Oral cavity | OSCC | 7.75e-05 | 1.71e-01 | 0.1679 |
6405 | SEMA3F | C07 | Human | Oral cavity | OSCC | 1.30e-02 | 7.72e-01 | 0.2491 |
6405 | SEMA3F | LN46 | Human | Oral cavity | OSCC | 1.49e-03 | 1.98e-01 | 0.1666 |
6405 | SEMA3F | SYSMH1 | Human | Oral cavity | OSCC | 9.27e-15 | 3.37e-01 | 0.1127 |
6405 | SEMA3F | SYSMH2 | Human | Oral cavity | OSCC | 4.99e-07 | 2.07e-01 | 0.2326 |
6405 | SEMA3F | SYSMH3 | Human | Oral cavity | OSCC | 5.30e-24 | 5.15e-01 | 0.2442 |
6405 | SEMA3F | SYSMH4 | Human | Oral cavity | OSCC | 2.87e-05 | 7.42e-02 | 0.1226 |
6405 | SEMA3F | SYSMH5 | Human | Oral cavity | OSCC | 2.42e-04 | 9.38e-02 | 0.0647 |
6405 | SEMA3F | SYSMH6 | Human | Oral cavity | OSCC | 2.79e-04 | 9.29e-02 | 0.1275 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001604917 | Oral cavity | OSCC | cell growth | 268/7305 | 482/18723 | 6.55e-14 | 3.51e-12 | 268 |
GO:000155816 | Oral cavity | OSCC | regulation of cell growth | 228/7305 | 414/18723 | 1.74e-11 | 6.09e-10 | 228 |
GO:003253519 | Oral cavity | OSCC | regulation of cellular component size | 201/7305 | 383/18723 | 4.80e-08 | 8.88e-07 | 201 |
GO:00459266 | Oral cavity | OSCC | negative regulation of growth | 135/7305 | 249/18723 | 7.29e-07 | 1.03e-05 | 135 |
GO:00303084 | Oral cavity | OSCC | negative regulation of cell growth | 101/7305 | 188/18723 | 2.85e-05 | 2.63e-04 | 101 |
GO:000166719 | Oral cavity | OSCC | ameboidal-type cell migration | 228/7305 | 475/18723 | 3.46e-05 | 3.10e-04 | 228 |
GO:00507679 | Oral cavity | OSCC | regulation of neurogenesis | 179/7305 | 364/18723 | 4.49e-05 | 3.84e-04 | 179 |
GO:001097510 | Oral cavity | OSCC | regulation of neuron projection development | 210/7305 | 445/18723 | 2.35e-04 | 1.52e-03 | 210 |
GO:00485889 | Oral cavity | OSCC | developmental cell growth | 116/7305 | 234/18723 | 6.20e-04 | 3.50e-03 | 116 |
GO:00605609 | Oral cavity | OSCC | developmental growth involved in morphogenesis | 116/7305 | 234/18723 | 6.20e-04 | 3.50e-03 | 116 |
GO:00083618 | Oral cavity | OSCC | regulation of cell size | 92/7305 | 181/18723 | 7.86e-04 | 4.26e-03 | 92 |
GO:00519605 | Oral cavity | OSCC | regulation of nervous system development | 205/7305 | 443/18723 | 9.80e-04 | 5.11e-03 | 205 |
GO:19901388 | Oral cavity | OSCC | neuron projection extension | 86/7305 | 172/18723 | 2.13e-03 | 9.80e-03 | 86 |
GO:00486759 | Oral cavity | OSCC | axon extension | 61/7305 | 120/18723 | 5.52e-03 | 2.14e-02 | 61 |
GO:00509204 | Oral cavity | OSCC | regulation of chemotaxis | 105/7305 | 223/18723 | 8.27e-03 | 3.01e-02 | 105 |
GO:00313458 | Oral cavity | OSCC | negative regulation of cell projection organization | 89/7305 | 186/18723 | 8.51e-03 | 3.09e-02 | 89 |
GO:006156410 | Oral cavity | OSCC | axon development | 207/7305 | 467/18723 | 1.01e-02 | 3.51e-02 | 207 |
GO:00487627 | Oral cavity | OSCC | mesenchymal cell differentiation | 109/7305 | 236/18723 | 1.43e-02 | 4.69e-02 | 109 |
GO:00488637 | Oral cavity | OSCC | stem cell differentiation | 96/7305 | 206/18723 | 1.55e-02 | 4.99e-02 | 96 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0436014 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
hsa0436015 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
SEMA3F | NRP2_PLXNA2 | SEMA3F_NRP2_PLXNA2 | SEMA3 | Cervix | CC |
SEMA3F | NRP2_PLXNA2 | SEMA3F_NRP2_PLXNA2 | SEMA3 | CRC | AD |
SEMA3F | NRP2_PLXNA2 | SEMA3F_NRP2_PLXNA2 | SEMA3 | CRC | MSI-H |
SEMA3F | NRP2_PLXNA2 | SEMA3F_NRP2_PLXNA2 | SEMA3 | Esophagus | ESCC |
SEMA3F | NRP2_PLXNA1 | SEMA3F_NRP2_PLXNA1 | SEMA3 | HNSCC | OSCC |
SEMA3F | NRP2_PLXNA2 | SEMA3F_NRP2_PLXNA2 | SEMA3 | HNSCC | OSCC |
SEMA3F | NRP2_PLXNA1 | SEMA3F_NRP2_PLXNA1 | SEMA3 | HNSCC | Precancer |
SEMA3F | NRP2_PLXNA2 | SEMA3F_NRP2_PLXNA2 | SEMA3 | HNSCC | Precancer |
SEMA3F | NRP2_PLXNA2 | SEMA3F_NRP2_PLXNA2 | SEMA3 | Prostate | Tumor |
SEMA3F | NRP2_PLXNA1 | SEMA3F_NRP2_PLXNA1 | SEMA3 | THCA | ADJ |
SEMA3F | NRP2_PLXNA2 | SEMA3F_NRP2_PLXNA2 | SEMA3 | THCA | ADJ |
SEMA3F | NRP2_PLXNA3 | SEMA3F_NRP2_PLXNA3 | SEMA3 | THCA | ADJ |
SEMA3F | NRP2_PLXNA1 | SEMA3F_NRP2_PLXNA1 | SEMA3 | THCA | Cancer |
SEMA3F | NRP2_PLXNA3 | SEMA3F_NRP2_PLXNA3 | SEMA3 | THCA | Cancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SEMA3F | SNV | Missense_Mutation | novel | c.1637A>G | p.His546Arg | p.H546R | Q13275 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-97-A4LX-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SEMA3F | SNV | Missense_Mutation | novel | c.1426G>C | p.Gly476Arg | p.G476R | Q13275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-MN-A4N1-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SEMA3F | SNV | Missense_Mutation | c.913N>T | p.Gly305Cys | p.G305C | Q13275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-18-3416-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
SEMA3F | SNV | Missense_Mutation | c.46N>T | p.Ala16Ser | p.A16S | Q13275 | protein_coding | tolerated(0.28) | benign(0.124) | TCGA-18-3417-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | cisplatin | SD | |
SEMA3F | SNV | Missense_Mutation | novel | c.1229N>T | p.Gly410Val | p.G410V | Q13275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-34-2605-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | cisplatin | PD |
SEMA3F | SNV | Missense_Mutation | c.834N>A | p.Phe278Leu | p.F278L | Q13275 | protein_coding | deleterious(0.04) | benign(0.033) | TCGA-CQ-7071-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
SEMA3F | SNV | Missense_Mutation | c.2013N>A | p.Ser671Arg | p.S671R | Q13275 | protein_coding | tolerated(0.39) | benign(0.346) | TCGA-CV-5977-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SEMA3F | SNV | Missense_Mutation | novel | c.2224A>T | p.Ile742Phe | p.I742F | Q13275 | protein_coding | deleterious(0.01) | possibly_damaging(0.545) | TCGA-CV-7254-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
SEMA3F | SNV | Missense_Mutation | novel | c.1606N>G | p.Ser536Ala | p.S536A | Q13275 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-QK-A8ZA-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
SEMA3F | SNV | Missense_Mutation | rs200910175 | c.1889N>T | p.Ser630Leu | p.S630L | Q13275 | protein_coding | deleterious(0) | benign(0.436) | TCGA-J9-A52C-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |